Long-term bezafibrate use shows promise for managing canine hypertriglyceridemia

Hypertriglyceridemia remains a common yet underrecognized metabolic abnormality in dogs, particularly in patients with endocrine disease or breed predispositions. Although dietary fat restriction and ω-3 supplementation are considered first-line management strategies, more severe or refractory cases frequently require pharmacologic intervention. A recent study published in the Journal of Veterinary Internal Medicine evaluated the long-term safety and efficacy of bezafibrate (BZF), offering new clinical insight into its role in managing both primary and secondary hypertriglyceridemia.¹

Why this study matters

Hypertriglyceridemia in dogs is typically secondary to underlying conditions such as diabetes mellitus, hypothyroidism, or hyperadrenocorticism, though primary (idiopathic or breed-associated) forms also occur.¹ If left unmanaged, elevated triglyceride concentrations have been associated with clinically significant sequelae, including pancreatitis, insulin resistance, gallbladder mucocele, and seizures.¹

Although fibrates are widely used in human medicine to manage dyslipidemia, veterinary data regarding long-term use have been limited. This study helps fill that gap by evaluating outcomes beyond the short-term treatment window previously described.

Study design and population

Investigators conducted a retrospective analysis of 55 client-owned dogs treated with BZF for clinically relevant hypertriglyceridemia (defined as triglycerides > 221 mg/dL).¹ Dogs were categorized into the following 3 groups:

• Primary hypertriglyceridemia
• Secondary hypertriglyceridemia with stable underlying disease management
• Secondary hypertriglyceridemia with changes in treatment over time

Dogs received once-daily oral BZF at a median starting dose of 5.5 mg/kg, with follow-up data collected at intervals up to and beyond 18 months.¹

Treatment response was defined as a 50% or greater reduction in baseline triglyceride concentration.

Key findings

Robust triglyceride reduction across groups

BZF therapy resulted in significant and sustained reductions in triglyceride concentrations across all groups. Median triglyceride reduction reached approximately 85% over the study period.¹

Importantly, there were no significant differences in final triglyceride concentrations between dogs with primary vs secondary disease, suggesting consistent efficacy regardless of underlying etiology.¹

Short-term response was also strong, with 97% of dogs achieving an adequate response within 1 month of treatment initiation.¹

Efficacy despite incomplete disease control

In dogs with secondary hypertriglyceridemia, triglyceride concentrations improved even when the underlying disease was not optimally controlled.¹ This finding supports the use of fibrates as part of a multimodal management strategy, particularly in cases where endocrine disease stabilization is incomplete or delayed.

Favorable safety profile

Adverse effects were uncommon, occurring in 4 of 55 dogs (7%).¹ Reported issues were primarily gastrointestinal or biochemical (eg, increased alanine aminotransferase activity).

No consistent increase in creatine kinase activity was observed, and most dogs tolerated long-term therapy well.¹

Clinical implications

These findings reinforce BZF as a viable option for dogs with moderate to severe hypertriglyceridemia, particularly when dietary management alone is insufficient.

Key clinical takeaways include the following:

• High efficacy: Most dogs experience rapid and substantial triglyceride reduction
• Broad applicability: Effective in both primary and secondary hypertriglyceridemia
• Adjunctive role: Can be used alongside the management of underlying diseases
• Monitoring still required: Periodic evaluation of hepatic enzymes and clinical signs is recommended

The study also highlights an important clinical nuance. Although addressing underlying disease remains essential, pharmacologic triglyceride reduction may still provide benefit even when endocrine control is suboptimal.

Limitations to consider

As a retrospective study, the analysis is subject to inherent limitations, including the following:

• Nonstandardized follow-up intervals
• Variability in diet and concurrent therapies
• Potential misclassification between primary and secondary hypertriglyceridemia

Additionally, the lack of standardized imaging follow-up means potential long-term risks such as cholelithiasis—reported in human fibrate use—were not assessed.¹

What comes next

The authors emphasize the need for prospective, standardized trials to further validate dosing strategies, long-term safety, and comparative efficacy with other lipid-lowering agents.¹

For now, this study provides strong real-world evidence supporting BZF as an effective, generally well-tolerated option for the veterinary management of canine hypertriglyceridemia.

Reference

Castonguay-Poirier M, Fifle L, Javard R, Huvé R. Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia. J Vet Intern Med. 2026;40(2):aalag041. doi:10.1093/jvimsj/aalag041